Results 221 to 230 of about 1,268,660 (340)

A FAN1 point mutation associated with accelerated Huntington's disease progression alters its PCNA-mediated assembly on DNA. [PDF]

Nat Commun
Aretz J, Jeyasankar G, Salerno-Kochan A, Thomsen M, Thieulin-Pardo G, Haque T, Monteagudo E, Felsenfeld D, Finley M, Vogt TF, Boudet J, Prasad BC.   +11 more
europepmc   +1 more source

FGFR2 point mutation in 2 cases of pleomorphic adenoma progressing to myoepithelial carcinoma. [PDF]

Contemp Oncol (Pozn), 2023
Pikul J, Rzepakowska A, Machnicki M, Stokłosa T.   +3 more
europepmc   +1 more source

A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas [PDF]

, 2004
Zhen-Hua Lin, Eun Mee Han, Eung Seok Lee, Chul Whan Kim, Han Kyeom Kim, Insun Kim, Young‐Sik Kim   +6 more
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

A single point mutation is sufficient to drive <i>syp</i>-dependent biofilm formation and promote colonization by <i>Vibrio fischeri</i>. [PDF]

J Bacteriol
Fung BL, Musto EG, Mugambi LK, Lange ML, Tepavcevic J, Visick KL.   +5 more
europepmc   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

A point mutation in the photosystem II protein PsbW disrupts thylakoid organization and alters starch granule formation. [PDF]

Plant Physiol
Ilse TE, Zhang H, Heutinck A, Liu C, Eicke S, Sharma M, Pfister B, Santelia D, Zeeman SC.   +8 more
europepmc   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

T315I - a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia. [PDF]

Adv Lab Med
Kaleem B, Shahab S, Shamsi TS.
europepmc   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source